Expanded Access: Past, Present and Future Improvements
Additional Concepts, Closeout, EAP, Execution, Forecasting / Planning
Expanded access is a program that provides patients with investigational medicinal products (IMP) for treatment purposes. These patients are often excluded from clinical trials but could still benefit from access to the drugs, biologics or medical devices being tested. While, in concept, expanded access represents a way to help more patients receive new and developing treatments, in reality, the process is complex and often misunderstood.
Related Education Resources.
All ResourcesLessons Learned: Conducting COVID Clinical Trials and Building a Clinical Supplies Team During the Peak of the Pandemic
Topics: Conference, COVID-19
Executive Summary
Members
Environmental Sustainability & the Supply of Medicines for Use in Clinical Trials
Topic: Supply Chain
White Paper
Free
COVID-19 and the Clinical Supply Chain: Mitigating Risk and Maintaining Business Continuity
Topics: COVID-19, Pharma Industry, Supply Chain
Position Paper
Free
